{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:04:02Z","timestamp":1788210242623,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T00:00:00Z","timestamp":1279584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100006689","name":"Associazione Sarda per la ricerca nell\u2019Oncologia Ginecologica-ONLUS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006689","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia of chronic inflammatory diseases characterized by specific changes in iron homeostasis and absorption. i.v. iron improves the efficacy of recombinant human erythropoietin (rHuEPO) in anemic cancer patients undergoing chemotherapy. We report the results of an open-label, randomized, prospective trial aimed at testing the efficacy and safety of treatment with oral lactoferrin versus i.v. iron, both combined with rHuEPO, for the treatment of anemia in a population of 148 advanced cancer patients undergoing chemotherapy. All patients received s.c. rHuEPO-\u03b2, 30,000 UI once weekly for 12 weeks, and were randomly assigned to ferric gluconate (125 mg i.v. weekly) or lactoferrin (200 mg\/day). Both arms showed a significant hemoglobin increase. No difference in the mean hemoglobin increase or the hematopoietic response, time to hematopoietic response, or mean change in serum iron, C-reactive protein, or erythrocyte sedimentation rate were observed between arms. In contrast, ferritin decreased in the lactoferrin arm whereas it increased in the i.v. iron arm. In conclusion, these results show similar efficacy for oral lactoferrin and for i.v. iron, combined with rHuEPO, for the treatment of anemia in advanced cancer patients undergoing chemotherapy.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0020","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T03:49:04Z","timestamp":1279684144000},"page":"894-902","source":"Crossref","is-referenced-by-count":54,"title":["Efficacy and Safety of Oral Lactoferrin Supplementation in Combination with rHuEPO-\u03b2 for the Treatment of Anemia in Advanced Cancer Patients Undergoing Chemotherapy: Open-Label, Randomized Controlled Study"],"prefix":"10.1093","volume":"15","author":[{"given":"Antonio","family":"Macci\u00f2","sequence":"first","affiliation":[{"name":"a Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Madeddu","sequence":"additional","affiliation":[{"name":"b Department of Medical Oncology, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gramignano","sequence":"additional","affiliation":[{"name":"c Medical Oncology Unit, \u201cN.S. Bonaria\u201d Hospital, San Gavino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Mulas","sequence":"additional","affiliation":[{"name":"a Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sanna","sequence":"additional","affiliation":[{"name":"a Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Mantovani","sequence":"additional","affiliation":[{"name":"b Department of Medical Oncology, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,7,20]]},"reference":[{"issue":"suppl 7A","key":"2021122207515678600_R1","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: A systematic review of the literature","volume":"116","author":"Knight","year":"2004","journal-title":"Am J Med"},{"key":"2021122207515678600_R2","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: Incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2021122207515678600_R3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2005-01-0160","article-title":"Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia","volume":"106","author":"Macci\u00f2","year":"2005","journal-title":"Blood"},{"key":"2021122207515678600_R4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc1648","article-title":"The anaemia of cancer: Death by a thousand cuts","volume":"5","author":"Spivak","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2021122207515678600_R5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199006143222401","article-title":"Decreased erythropoietin response in patients with the anemia of cancer","volume":"322","author":"Miller","year":"1990","journal-title":"N Engl J Med"},{"key":"2021122207515678600_R6","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood.V80.7.1639.1639","article-title":"Progress in understanding the pathogenesis of the anemia of chronic disease","volume":"80","author":"Means","year":"1992","journal-title":"Blood"},{"key":"2021122207515678600_R7","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"2021122207515678600_R8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semarthrit.2008.01.006","article-title":"Role of interleukin-6 in the anemia of chronic disease","volume":"38","author":"Raj","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"2021122207515678600_R9","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.bcp.2008.12.018","article-title":"Linking anemia to inflammation and cancer: The crucial role of TNF\u03b1","volume":"77","author":"Buck","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"2021122207515678600_R10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122207515678600_R11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"2021122207515678600_R12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI21441","article-title":"Anemia of inflammation: The cytokine-hepcidin link","volume":"113","author":"Andrews","year":"2004","journal-title":"J Clin Invest"},{"key":"2021122207515678600_R13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(07)60689-8","article-title":"Clinical update: Intravenous iron for anaemia","volume":"369","author":"Auerbach","year":"2007","journal-title":"Lancet"},{"issue":"301","key":"2021122207515678600_R14","first-page":"e1","article-title":"Lactoferrin: Structure, function and applications","volume":"33","author":"Gonz\u00e1lez-Ch\u00e1vez","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2021122207515678600_R15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/B:BIOM.0000027694.40260.70","article-title":"Lactoferrin and iron: Structural and dynamic aspects of binding and release","volume":"17","author":"Baker","year":"2004","journal-title":"Biometals"},{"key":"2021122207515678600_R16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update","volume":"26","author":"Rizzo","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207515678600_R17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.10-6-438","article-title":"Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve","volume":"10","author":"Duh","year":"2005","journal-title":"The Oncologist"},{"key":"2021122207515678600_R18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207515678600_R19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alpha versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"The Oncologist"},{"key":"2021122207515678600_R20","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"26","author":"Bastit","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207515678600_R21","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.2007.12.2051","article-title":"Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha","volume":"26","author":"Pedrazzoli","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207515678600_R22","first-page":"536","article-title":"; National Comprehensive Cancer Network","volume":"6","author":"Rodgers","year":"2008","journal-title":"Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw"},{"key":"2021122207515678600_R23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/cncr.23698","article-title":"Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy","volume":"113","author":"Cella","year":"2008","journal-title":"Cancer"},{"key":"2021122207515678600_R24","first-page":"1209","article-title":"Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients","volume":"87","author":"Beguin","year":"2002","journal-title":"Haematologica"},{"key":"2021122207515678600_R25","first-page":"2840","article-title":"Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens","volume":"17","author":"Ray-Coquard","year":"1999","journal-title":"The Elypse 1 Study Group. J Clin Oncol"},{"key":"2021122207515678600_R26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/ajcn\/83.2.305","article-title":"Absorption of iron from recombinant human lactoferrin in young US women","volume":"83","author":"L\u00f6nnerdal","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"2021122207515678600_R27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1089\/scd.2005.14.548","article-title":"Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapy-induced immunosuppression and bone marrow transplant in mice","volume":"14","author":"Artym","year":"2005","journal-title":"Stem Cells Dev"},{"key":"2021122207515678600_R28","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1158\/1078-0432.CCR-06-2008","article-title":"Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo","volume":"13","author":"Wolf","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122207515678600_R29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.20271","article-title":"Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy","volume":"111","author":"Varadhachary","year":"2004","journal-title":"Int J Cancer"},{"key":"2021122207515678600_R30","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"key":"2021122207515678600_R31","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2008.21.6945","article-title":"Erythroid-stimulating agents in cancer therapy: Potential dangers and biologic mechanisms","volume":"27","author":"Handland","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515678600_R32","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"issue":"suppl 16","key":"2021122207515678600_R33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.seminoncol.2003.08.020","article-title":"Erythropoietin as a critical component of breast cancer therapy: Survival, synergistic, and cognitive applications","volume":"30","author":"Leyland-Jones","year":"2003","journal-title":"Semin Oncol"},{"key":"2021122207515678600_R34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/8\/894\/41843557\/oncolo_15_8_894.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/8\/894\/41843557\/oncolo_15_8_894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T10:50:34Z","timestamp":1640170234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/8\/894\/6399398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,20]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2010,7,20]]},"published-print":{"date-parts":[[2010,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0020","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,8,1]]},"published":{"date-parts":[[2010,7,20]]}}}